Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara
Open accessThe DOI matches its Crossref record.
Abstract
Malaria is a major global health problem for which an effective vaccine is required urgently. Prime-boost vaccination regimes involving plasmid DNA and recombinant modified vaccinia virus Ankara-encoding liver-stage malaria antigens have been shown to be powerfully immunogenic for T cells and capable of inducing partial protection against experimental malaria challenge in humans, manifested as a delay in time to patent parasitemia. Here, we report that substitution of plasmid DNA as the priming vector with a specific attenuated recombinant fowlpox virus, FP9, vaccine in such prime-boost regimes can elicit complete sterile protection that can last for 20 months. Protection at 20 months was associated with persisting memory but not effector T cell responses. The protective efficacy of various immunization regimes correlated with the magnitude of induced immune responses, supporting the strategy of maximizing durable T cell immunogenicity to develop more effective liver-stage vaccines against Plasmodium falciparum malaria.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Viruses as vaccine vectors for infectious diseases and cancer
Draper, S. J., & Heeney, J. L. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2240 · Cited by 353
Modified Vaccinia Virus Ankara
Volz, A., & Sutter, G. (2017) · Advances in Virus Research · doi:10.1016/bs.aivir.2016.07.001 · Cited by 323
Crompton, P. D., Moebius, J., Portugal, S., Waisberg, M., Hart, G., Garver, L. S., Miller, L. H., Barillas-Mury, C., & Pierce, S. K. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120220 · Cited by 317
Technologies for enhanced efficacy of DNA vaccines
Saade, F., & Petrovsky, N. (2012) · Expert Review of Vaccines · doi:10.1586/erv.11.188 · Cited by 309
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
Ewer, K. J., O’Hara, G. A., Duncan, C. J. A., Collins, K. A., Sheehy, S. H., Reyes-Sandoval, A., Goodman, A. L., Edwards, N. J., Elias, S. C., Halstead, F. D., et al. (2013) · Nature Communications · doi:10.1038/ncomms3836 · Cited by 286
Self-citationVaccinia virus vaccines: Past, present and future
Jacobs, B. L., Langland, J. O., Kibler, K. V., Denzler, K. L., White, S. D., Holechek, S. A., Wong, S., Huynh, T., & Baskin, C. R. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.06.006 · Cited by 279
Advances and challenges in malaria vaccine development
Crompton, P. D., Pierce, S. K., & Miller, L. H. (2010) · Journal of Clinical Investigation · doi:10.1172/jci44423 · Cited by 269
Experimental human challenge infections can accelerate clinical malaria vaccine development
Sauerwein, R. W., Roestenberg, M., & Moorthy, V. S. (2011) · Nature Reviews Immunology · doi:10.1038/nri2902 · Cited by 267
Gene-based vaccines: recent technical and clinical advances
Ulmer, J. B., Wahren, B., & Liu, M. A. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.03.007 · Cited by 174
Dunachie, S. J., Walther, M., Epstein, J. E., Keating, S., Berthoud, T., Andrews, L., Andersen, R. F., Bejon, P., Goonetilleke, N., Poulton, I., et al. (2006) · Infection and Immunity · doi:10.1128/iai.00590-06 · Cited by 164
“A prime-boost regimen encoding the same ME-TRAP insert but utilizing two doses of fowlpox strain 9 ME-TRAP boosted by one dose of MVA ME-TRAP has previously resulted in complete protection against malaria in a similar protocol in Oxford, United Kingdom (57).”
MethodInfluentialSelf-citationViral vectors for vaccine applications
Choi, Y., & Chang, J. (2013) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2013.2.2.97 · Cited by 112
Metadata
- Authors
- Webster, D. P., Dunachie, S., Vuola, J. M., Berthoud, T., Keating, S., Laidlaw, S. M., McConkey, S. J., Poulton, I., Andrews, L., Andersen, R. F., Bejon, P., Butcher, G., Sinden, R., Skinner, M. A., Gilbert, S. C., & Hill, A. V. S.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-03-21
- Volume
- 102
- Issue
- 13
- Pages
- 4836-4841
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2114643485
- Cited by
- 242
- References
- 0
- FWCI
- 30.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.